{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T04:10:40Z","timestamp":1711253440868},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2010,2,19]],"date-time":"2010-02-19T00:00:00Z","timestamp":1266537600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s12328-010-0139-z","type":"journal-article","created":{"date-parts":[[2010,2,18]],"date-time":"2010-02-18T03:09:07Z","timestamp":1266462547000},"page":"61-68","source":"Crossref","is-referenced-by-count":5,"title":["Maintenance therapy of gastroesophageal reflux disease"],"prefix":"10.1007","volume":"3","author":[{"given":"Akihito","family":"Nagahara","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariko","family":"Hojo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Asaoka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sumio","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2010,2,19]]},"reference":[{"key":"139_CR1","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1111\/j.1572-0241.2006.00630.x","volume":"101","author":"N Vakil","year":"2006","unstructured":"Vakil N, van Zanten SV, Kahrilas P, Dent J, Jones R. Global consensus group. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol. 2006;101:1900\u201320.","journal-title":"Am J Gastroenterol"},{"key":"139_CR2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1023\/A:1005600831851","volume":"46","author":"T Sugiyama","year":"2001","unstructured":"Sugiyama T, Nishikawa K, Komatsu Y, Ishizuka J, Mizushima T, Kumagai A, et al. Attributable risk of H. pylori in peptic ulcer disease: does declining prevalence of infection in general population explain increasing frequency of non-H. pylori ulcers? Dig Dis Sci. 2001;46:307\u201310.","journal-title":"Dig Dis Sci"},{"key":"139_CR3","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1136\/gut.41.4.452","volume":"41","author":"Y Kinoshita","year":"1997","unstructured":"Kinoshita Y, Kawanami C, Kishi K, Nakata H, Seino Y, Chiba T. Helicobacter pylori independent chronological change in gastric acid secretion in the Japanese. Gut. 1997;41:452\u20138.","journal-title":"Gut"},{"key":"139_CR4","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s12328-008-0039-7","volume":"1","author":"H Miwa","year":"2008","unstructured":"Miwa H, Oshima T, Tomita T, Kim Y, Hori K, Matsumoto T. Gastro-esophageal reflux disease: the recent trend in Japan. Clin J Gastroenterol. 2008;1:133\u20138.","journal-title":"Clin J Gastroenterol"},{"key":"139_CR5","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s00535-007-2033-0","volume":"42","author":"S Watanabe","year":"2007","unstructured":"Watanabe S, Hojo M, Nagahara A. Metabolic syndrome and gastrointestinal diseases. J Gastroenterol. 2007;42:267\u201374.","journal-title":"J Gastroenterol"},{"key":"139_CR6","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s005350050293","volume":"34","author":"N Furukawa","year":"1999","unstructured":"Furukawa N, Iwakiri R, Koyama T, Okamoto K, Yoshida T, Kashiwagi Y, et al. Proportion of reflux esophagitis in 6010 Japanese adults: prospective evaluation by endoscopy. J Gastroenterol. 1999;34:441\u20134.","journal-title":"J Gastroenterol"},{"key":"139_CR7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1007\/s001980200034","volume":"13","author":"T Yamaguchi","year":"2002","unstructured":"Yamaguchi T, Sugimoto T, Yamada H, Kanzawa M, Yano S, Yamauchi M, et al. The presence and severity of vertebral fractures is associated with the presence of esophageal hiatal hernia in postmenopausal women. Osteoporos Int. 2002;13:331\u20136.","journal-title":"Osteoporos Int"},{"key":"139_CR8","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.2169\/internalmedicine.47.1193","volume":"47","author":"M Yoshimura","year":"2008","unstructured":"Yoshimura M, Nagahara A, Ohtaka K, Shimada Y, Asaoka D, Kurosawa A, et al. Presence of vertebral fractures is highly associated with hiatal hernia and reflux esophagitis in Japanese elderly people. Intern Med. 2008;47:1451\u20135.","journal-title":"Intern Med"},{"key":"139_CR9","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1007\/s12328-009-0125-5","volume":"2","author":"K Iwakiri","year":"2009","unstructured":"Iwakiri K. The role of excessive esophageal acid exposure in patients with gastroesophageal reflux disease. Clin J Gastroenterol. 2009;2:371\u20139.","journal-title":"Clin J Gastroenterol"},{"key":"139_CR10","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1007\/s00535-009-0047-5","volume":"44","author":"Y Fujiwara","year":"2009","unstructured":"Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518\u201334.","journal-title":"J Gastroenterol"},{"key":"139_CR11","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1111\/j.1365-2036.2008.03804.x","volume":"28","author":"D Armstrong","year":"2008","unstructured":"Armstrong D. Systematic review: persistence and severity in gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2008;28:841\u201353.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR12","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/01.mcg.0000225631.07039.6d","volume":"41","author":"R Fass","year":"2007","unstructured":"Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol. 2007;41:131\u20137.","journal-title":"J Clin Gastroenterol"},{"issue":"3 Suppl","key":"139_CR13","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0002-9270(03)00009-1","volume":"98","author":"R Fass","year":"2003","unstructured":"Fass R. Epidemiology and pathophysiology of symptomatic gastroesophageal reflux disease. Am J Gastroenterol. 2003;98(3 Suppl):S2\u20137.","journal-title":"Am J Gastroenterol"},{"key":"139_CR14","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1111\/j.1572-0241.2005.40966.x","volume":"100","author":"Y Fujiwara","year":"2005","unstructured":"Fujiwara Y, Higuchi K, Shiba M, Yamamori K, Watanabe Y, Sasaki E, et al. Differences in clinical characteristics between patients with endoscopy-negative reflux disease and erosive esophagitis in Japan. Am J Gastroenterol. 2005;100:754\u20138.","journal-title":"Am J Gastroenterol"},{"issue":"Suppl 1","key":"139_CR15","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1111\/j.1365-2036.2004.01990.x","volume":"20","author":"H Miwa","year":"2004","unstructured":"Miwa H, Minoo T, Hojo M, Yaginuma R, Nagahara A, Kawabe M, et al. Oesophageal hypersensitivity in Japanese patients with non-erosive gastro-oesophageal reflux diseases. Aliment Pharmacol Ther. 2004;20(Suppl 1):112\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR16","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1097\/01.mcg.0000225673.76475.9d","volume":"40","author":"A Nagahara","year":"2006","unstructured":"Nagahara A, Miwa H, Minoo T, Hojo M, Kawabe M, Osada T, et al. Increased esophageal sensitivity to acid and saline in patients with nonerosive gastro-esophageal reflux disease. J Clin Gastroenterol. 2006;40:891\u20135.","journal-title":"J Clin Gastroenterol"},{"key":"139_CR17","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1046\/j.1365-2036.1997.00167.x","volume":"11","author":"R Carlsson","year":"1997","unstructured":"Carlsson R, Galmiche JP, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther. 1997;11:473\u201382.","journal-title":"Aliment Pharmacol Ther"},{"issue":"Suppl 3","key":"139_CR18","doi-asserted-by":"crossref","first-page":"S54","DOI":"10.1111\/j.1440-1746.2004.03590.x","volume":"19","author":"WM Wong","year":"2004","unstructured":"Wong WM, Lim P, Wong BC. Clinical practice pattern of gastroenterologists, primary care physicians, and otolaryngologists for the management of GERD in the Asia-Pacific region: the FAST survey. J Gastroenterol Hepatol. 2004;19(Suppl 3):S54\u201360.","journal-title":"J Gastroenterol Hepatol"},{"key":"139_CR19","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/0149-2918(95)80093-X","volume":"17","author":"TJ Simon","year":"1995","unstructured":"Simon TJ, Roberts WG, Berlin RG, Hayden LJ, Berman RS, Reagan JE. Acid suppression by famotidine 20\u00a0mg twice daily or 40\u00a0mg twice daily in preventing relapse of endoscopic recurrence of erosive esophagitis. Clin Ther. 1995;17:1147\u201356.","journal-title":"Clin Ther"},{"key":"139_CR20","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1111\/j.1440-1746.2005.03980.x","volume":"20","author":"S Mine","year":"2005","unstructured":"Mine S, Iida T, Tabata T, Kishikawa H, Tanaka Y. Management of symptoms in step-down therapy of gastroesophageal reflux disease. J Gastroenterol Hepatol. 2005;20:1365\u201370.","journal-title":"J Gastroenterol Hepatol"},{"key":"139_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000018685","volume":"16","author":"GN Tytgat","year":"1999","unstructured":"Tytgat GN. Possibilities and shortcomings of maintenance therapy in gastroesophageal reflux disease. Dig Surg. 1999;16:1\u20136.","journal-title":"Dig Surg"},{"key":"139_CR22","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1111\/j.1572-0241.1999.989_l.x","volume":"94","author":"HP Festen","year":"1999","unstructured":"Festen HP, Schenk E, Tan G, Snel P, Nelis F. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. The Dutch Reflux Study Group. Am J Gastroenterol. 1999;94:931\u20136.","journal-title":"Am J Gastroenterol"},{"key":"139_CR23","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1136\/bmj.318.7182.502","volume":"318","author":"KD Bardhan","year":"1999","unstructured":"Bardhan KD, M\u00fcller-Lissner S, Bigard MA, Bianchi Porro G, Ponce J, Hosie J, et al. Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine. The European Study Group. BMJ. 1999;318:502\u20137.","journal-title":"BMJ"},{"key":"139_CR24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.5694\/j.1326-5377.2002.tb04882.x","volume":"177","author":"NJ Talley","year":"2002","unstructured":"Talley NJ, Moore MG, Sprogis A, Katelaris P. Randomised controlled trial of pantoprazole versus ranitidine for the treatment of uninvestigated heartburn in primary care. Med J Aust. 2002;177:423\u20137.","journal-title":"Med J Aust"},{"key":"139_CR25","doi-asserted-by":"crossref","first-page":"839","DOI":"10.3109\/00365529509101589","volume":"30","author":"LS Laursen","year":"1995","unstructured":"Laursen LS, Havelund T, Bondesen S, Hansen J, Sanchez G, Sebelin E, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomized dose-finding study. Scand J Gastroenterol. 1995;30:839\u201346.","journal-title":"Scand J Gastroenterol"},{"key":"139_CR26","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1046\/j.1365-2036.2001.01024.x","volume":"15","author":"NB Vakil","year":"2001","unstructured":"Vakil NB, Shaker R, Johnson DA, Kovacs T, Baerg RD, Hwang C, et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther. 2001;15:927\u201335.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR27","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1097\/00042737-200012040-00010","volume":"12","author":"K Plein","year":"2000","unstructured":"Plein K, Hotz J, Wurzer H, Fumagalli I, L\u00fchmann R, Schneider A. Pantoprazole 20\u00a0mg is an effective maintenance therapy for patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2000;12:425\u201332.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"139_CR28","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1023\/A:1005548318996","volume":"45","author":"B Thjodleifsson","year":"2000","unstructured":"Thjodleifsson B, Beker JA, Dekkers C, Bjaaland T, Finnegan V, Humphries TJ. Rabeprazole versus omeprazole in preventing relapse of erosive or ulcerative gastroesophageal reflux disease: a double-blind, multicenter, European trial. The European Rabeprazole Study Group. Dig Dis Sci. 2000;45:845\u201353.","journal-title":"Dig Dis Sci"},{"key":"139_CR29","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1046\/j.1365-2036.2003.01464.x","volume":"17","author":"K Lauritsen","year":"2003","unstructured":"Lauritsen K, Devi\u00e8re J, Bigard MA, Bayerd\u00f6rffer E, M\u00f3zsik G, Murray F, et al. Esomeprazole 20\u00a0mg and lansoprazole 15\u00a0mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther. 2003;17:333\u201341.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR30","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1111\/j.1365-2036.2005.02643.x","volume":"22","author":"J Labenz","year":"2005","unstructured":"Labenz J, Armstrong D, Lauritsen K, Katelaris P, Schmidt S, Sch\u00fctze K, et al. Esomeprazole 20\u00a0mg vs. pantoprazole 20\u00a0mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study. Aliment Pharmacol Ther. 2005;22:803\u201311.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR31","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.cgh.2006.03.006","volume":"4","author":"KR Devault","year":"2006","unstructured":"Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB. Maintenance of healed erosive esophagitis: a randomized six-month comparison of esomeprazole twenty milligrams with lansoprazole fifteen milligrams. Clin Gastroenterol Hepatol. 2006;4:852\u20139.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"139_CR32","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1097\/MEG.0b013e32801055d5","volume":"19","author":"KL Goh","year":"2007","unstructured":"Goh KL, Benamouzig R, Sander P, Schwan T. EMANCIPATE. Efficacy of pantoprazole 20\u00a0mg daily compared with esomeprazole 20\u00a0mg daily in the maintenance of healed gastroesophageal reflux disease: a randomized, double-blind comparative trial\u2014the EMANCIPATE study. Eur J Gastroenterol Hepatol. 2007;19:205\u201311.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"139_CR33","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1046\/j.1365-2036.1997.00246.x","volume":"11","author":"JG Hatlebakk","year":"1997","unstructured":"Hatlebakk JG, Berstad A. Prognostic factors for relapse of reflux oesophagitis and symptoms during 12\u00a0months of therapy with lansoprazole. Aliment Pharmacol Ther. 1997;11:1093\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR34","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1046\/j.1365-2036.1998.00278.x","volume":"12","author":"D Jaspersen","year":"1998","unstructured":"Jaspersen D, Diehl KL, Schoeppner H, Geyer P, Martens E. A comparison of omeprazole, lansoprazole and pantoprazole in the maintenance treatment of severe reflux oesophagitis. Aliment Pharmacol Ther. 1998;12:49\u201352.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR35","doi-asserted-by":"crossref","first-page":"627","DOI":"10.3109\/00365529708996509","volume":"32","author":"TL Venables","year":"1997","unstructured":"Venables TL, Newland RD, Patel AC, Hole J, Copeman MB, Turbitt ML. Maintenance treatment for gastro-oesophageal reflux disease. A placebo-controlled evaluation of 10 milligrams omeprazole once daily in general practice. Scand J Gastroenterol. 1997;32:627\u201332.","journal-title":"Scand J Gastroenterol"},{"key":"139_CR36","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1046\/j.1365-2036.2002.01348.x","volume":"16","author":"T Saitoh","year":"2002","unstructured":"Saitoh T, Fukushima Y, Otsuka H, Hirakawa J, Mori H, Asano T, et al. Effects of rabeprazole, lansoprazole and omeprazole on intragastric pH in CYP2C19 extensive metabolizers. Aliment Pharmacol Ther. 2002;16:1811\u20137.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR37","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1046\/j.1365-2036.2001.01108.x","volume":"15","author":"N Shirai","year":"2001","unstructured":"Shirai N, Furuta T, Moriyama Y, Okochi H, Kobayashi K, Takashima M, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther. 2001;15:1929\u201337.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR38","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1067\/mcp.2001.119721","volume":"70","author":"T Furuta","year":"2001","unstructured":"Furuta T, Shirai N, Xiao F, Ohashi K, Ishizaki T. Effect of high-dose lansoprazole on intragastic pH in subjects who are homozygous extensive metabolizers of cytochrome P4502C19. Clin Pharmacol Ther. 2001;70:484\u201392.","journal-title":"Clin Pharmacol Ther"},{"key":"139_CR39","doi-asserted-by":"crossref","first-page":"153","DOI":"10.2133\/dmpk.20.153","volume":"20","author":"T Furuta","year":"2005","unstructured":"Furuta T, Shirai N, Sugimoto M, Nakamura A, Hishida A, Ishizaki T. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies. Drug Metab Pharmacokinet. 2005;20:153\u201367.","journal-title":"Drug Metab Pharmacokinet"},{"key":"139_CR40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.2174\/157488407779422302","volume":"2","author":"J Rosemary","year":"2007","unstructured":"Rosemary J, Adithan C. The pharmacogenetics of CYP2C9 and CYP2C19: ethnic variation and clinical significance. Curr Clin Pharmacol. 2007;2:93\u2013109.","journal-title":"Curr Clin Pharmacol"},{"key":"139_CR41","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/sj.clpt.6100043","volume":"81","author":"T Furuta","year":"2007","unstructured":"Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521\u20138.","journal-title":"Clin Pharmacol Ther"},{"key":"139_CR42","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1111\/j.1440-1746.2006.04419.x","volume":"22","author":"M Kawamura","year":"2007","unstructured":"Kawamura M, Ohara S, Koike T, Iijima K, Suzuki H, Kayaba S, et al. Cytochrome P450 2C19 polymorphism influences the preventive effect of lansoprazole on the recurrence of erosive reflux esophagitis. J Gastroenterol Hepatol. 2007;22:222\u20136.","journal-title":"J Gastroenterol Hepatol"},{"key":"139_CR43","first-page":"703","volume":"56","author":"T Saitoh","year":"2009","unstructured":"Saitoh T, Otsuka H, Kawasaki T, Endo H, Iga D, Tomimatsu M, et al. Influences of CYP2C19 polymorphism on recurrence of reflux esophagitis during proton pump inhibitor maintenance therapy. Hepatogastroenterology. 2009;56:703\u20136.","journal-title":"Hepatogastroenterology"},{"key":"139_CR44","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s00228-009-0628-5","volume":"65","author":"T Furuta","year":"2009","unstructured":"Furuta T, Sugimoto M, Kodaira C, Nishino M, Yamade M, Ikuma M, et al. CYP2C19 genotype is associated with symptomatic recurrence of GERD during maintenance therapy with low-dose lansoprazole. Eur J Clin Pharmacol. 2009;65:693\u20138.","journal-title":"Eur J Clin Pharmacol"},{"key":"139_CR45","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1111\/j.1365-2036.2005.02486.x","volume":"21","author":"T Ohkusa","year":"2005","unstructured":"Ohkusa T, Maekawa T, Arakawa T, Nakajima M, Fujimoto K, Hoshino E, et al. Effect of CYP2C19 polymorphism on the safety and efficacy of omeprazole in Japanese patients with recurrent reflux oesophagitis. Aliment Pharmacol Ther. 2005;21:1331\u20139.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR46","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1111\/j.1365-2036.2005.02558.x","volume":"22","author":"F Pace","year":"2005","unstructured":"Pace F, Negrini C, Wiklund I, Rossi C, Savarino V. ITALIAN ONE INVESTIGATORS STUDY GROUP Quality of life in acute and maintenance treatment of non-erosive and mild erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2005;22:349\u201356.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR47","first-page":"336","volume":"51","author":"D Cibor","year":"2006","unstructured":"Cibor D, Cie\u0107ko-Michalska I, Owczarek D, Szczepanek M. Optimal maintenance therapy in patients with non-erosive reflux disease reporting mild reflux symptoms\u2014a pilot study. Adv Med Sci. 2006;51:336\u20139.","journal-title":"Adv Med Sci"},{"key":"139_CR48","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1155\/2007\/203201","volume":"21","author":"DG Morgan","year":"2007","unstructured":"Morgan DG, O\u2019Mahony MF, O\u2019Mahony WF, Roy J, Camacho F, Dinniwell J, et al. Maintenance treatment of gastroesophageal reflux disease: an evaluation of continuous and on-demand therapy with rabeprazole 20\u00a0mg. Can J Gastroenterol. 2007;21:820\u20136.","journal-title":"Can J Gastroenterol"},{"key":"139_CR49","first-page":"67","volume":"56","author":"B Tepes","year":"2009","unstructured":"Tepes B, Stabuc B, Kocijancic B, Ivanusa M. Maintenance therapy of gastroesophageal reflux disease patients with omeprazole. Hepatogastroenterology. 2009;56:67\u201374.","journal-title":"Hepatogastroenterology"},{"key":"139_CR50","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1080\/00365520212499","volume":"37","author":"F Johnsson","year":"2002","unstructured":"Johnsson F, Moum B, Vilien M, Grove O, Simren M, Thoring M. On-demand treatment in patients with oesophagitis and reflux symptoms: comparison of lansoprazole and omeprazole. Scand J Gastroenterol. 2002;37:642\u20137.","journal-title":"Scand J Gastroenterol"},{"key":"139_CR51","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1111\/j.1365-2036.2004.01999.x","volume":"20","author":"P Bytzer","year":"2004","unstructured":"Bytzer P, Blum A, De Herdt D, Dubois D. Trial Investigators. Six-month trial of on-demand rabeprazole 10\u00a0mg maintains symptom relief in patients with non-erosive reflux disease. Aliment Pharmacol Ther. 2004;20:181\u20138.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR52","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1111\/j.1365-2036.2004.02155.x","volume":"20","author":"HH Tsai","year":"2004","unstructured":"Tsai HH, Chapman R, Shepherd A, McKeith D, Anderson M, Vearer D, et al. Esomeprazole 20\u00a0mg on-demand is more acceptable to patients than continuous lansoprazole 15\u00a0mg in the long-term maintenance of endoscopy-negative gastro-oesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther. 2004;20:657\u201365.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR53","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1111\/j.1368-5031.2005.00564.x","volume":"59","author":"A Norman Hansen","year":"2005","unstructured":"Norman Hansen A, Bergheim R, Fagertun H, Lund H, Moum B. A randomised prospective study comparing the effectiveness of esomeprazole treatment strategies in clinical practice for 6\u00a0months in the management of patients with symptoms of gastroesophageal reflux disease. Int J Clin Pract. 2005;59:665\u201371.","journal-title":"Int J Clin Pract"},{"key":"139_CR54","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1111\/j.1365-2036.2007.03381.x","volume":"26","author":"F Pace","year":"2007","unstructured":"Pace F, Tonini M, Pallotta S, Molteni P, Porro GB. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken \u2018on-demand\u2019. Aliment Pharmacol Ther. 2007;26:195\u2013204.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR55","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1046\/j.1365-2036.2001.01105.x","volume":"15","author":"K Geboes","year":"2001","unstructured":"Geboes K, Dekker W, Mulder CJ, Nusteling K. Dutch Study Group. Long-term lansoprazole treatment for gastro-oesophageal reflux disease: clinical efficacy and influence on gastric mucosa. Aliment Pharmacol Ther. 2001;15:1819\u201326.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR56","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1046\/j.1365-2036.2003.01446.x","volume":"17","author":"B Thjodleifsson","year":"2003","unstructured":"Thjodleifsson B, Rindi G, Fiocca R, Humphries TJ, Morocutti A, Miller N, et al. A randomized, double-blind trial of the efficacy and safety of 10 or 20\u00a0mg rabeprazole compared with 20\u00a0mg omeprazole in the maintenance of gastro-oesophageal reflux disease over 5\u00a0years. Aliment Pharmacol Ther. 2003;17:343\u201351.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR57","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1111\/j.1365-2036.2005.02555.x","volume":"22","author":"A Caos","year":"2005","unstructured":"Caos A, Breiter J, Perdomo C, Barth J. Long-term prevention of erosive or ulcerative gastro-oesophageal reflux disease relapse with rabeprazole 10 or 20\u00a0mg vs. placebo: results of a 5-year study in the United States. Aliment Pharmacol Ther. 2005;22:193\u2013202.","journal-title":"Aliment Pharmacol Ther"},{"key":"139_CR58","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1440-1746.2007.04871.x","volume":"22","author":"M Miyamoto","year":"2007","unstructured":"Miyamoto M, Haruma K, Kuwabara M, Nagano M, Okamoto T, Tanaka M. Long-term gastroesophageal reflux disease therapy improves reflux symptoms in elderly patients: five-year prospective study in community medicine. J Gastroenterol Hepatol. 2007;22:639\u201344.","journal-title":"J Gastroenterol Hepatol"},{"issue":"1","key":"139_CR59","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/j.1443-9573.2007.00278.x","volume":"8","author":"K Miki","year":"2007","unstructured":"Miki K, Urita Y. Using serum pepsinogens wisely in a clinical practice. J Dig Dis. 2007;8(1):8\u201314.","journal-title":"J Dig Dis"},{"key":"139_CR60","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/BF02774209","volume":"22","author":"K Miki","year":"1987","unstructured":"Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, et al. Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn. 1987;22:133\u201341.","journal-title":"Gastroenterol Jpn"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-010-0139-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12328-010-0139-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-010-0139-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,24]],"date-time":"2024-03-24T03:36:43Z","timestamp":1711251403000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12328-010-0139-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,19]]},"references-count":60,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["139"],"URL":"https:\/\/doi.org\/10.1007\/s12328-010-0139-z","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,19]]}}}